In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity

OncoImmunology

Volumn 4, Issue 11, 2015, Pages

  Prchal Murphy, Michaela ^a   Witalisz Siepracka, Agnieszka ^a   Bednarik, Karoline T ^a   Putz, Eva Maria ^a   Gotthardt, Dagmar ^a   Meissl, Katrin ^a   Sexl, Veronika ^a   Müller, Mathias ^a   Strobl, Birgit ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

interferon ; interleukin 12; NK cells; tumor surveillance; tyrosine kinase 2

Indexed keywords

FOCAL ADHESION KINASE 1; GAMMA INTERFERON; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DEGRANULATION ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SPLEEN CELL; TRANSCRIPTION REGULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; WESTERN BLOTTING;

EID: 84941775673     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1047579     Document Type: Article

References (62)

1. B.Strobl, D.Stoiber, V.Sexl, M.Mueller. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front Biosci (Landmark Ed) 2011; 16:3214-32; PMID:21622231; http://dx.doi.org/10.2741/3908
2. M.Karaghiosoff, H.Neubauer, C.Lassnig, P.Kovarik, H.Schindler, H.Pircher, B.McCoy, C.Bogdan, T.Decker, G.Brem et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000; 13:549-60; PMID:11070173; http://dx.doi.org/10.1016/S1074-7613(00)00054-6
3. K.C.Sheehan, K.S.Lai, G.P.Dunn, A.T.Bruce, M.S.Diamond, J.D.Heutel, C.Dungo-Arthur, J.A.Carrero, J.M.White, P.J.Hertzog et al. Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J Interferon Cytokine Res 2006; 26:804-19; PMID:17115899; http://dx.doi.org/10.1089/jir.2006.26.804
4. K.Shimoda, K.Kato, K.Aoki, T.Matsuda, A.Miyamoto, M.Shibamori, M.Yamashita, A.Numata, K.Takase, S.Kobayashi et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000; 13:561-71; PMID:11070174; http://dx.doi.org/10.1016/S1074-7613(00)00055-8
5. M.H.Shaw, V.Boyartchuk, S.Wong, M.Karaghiosoff, J.Ragimbeau, S.Pellegrini, M.Muller, W.F.Dietrich, G.S.Yap. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad Sci U S A 2003; 100:11594-9; PMID:14500783; http://dx.doi.org/10.1073/pnas.1930781100
6. C.Ubel, S.Mousset, D.Trufa, H.Sirbu, S.Finotto. Establishing the role of tyrosine kinase 2 in cancer. Oncoimmunology 2013; 2:e22840; PMID:23482926; http://dx.doi.org/10.4161/onci.22840
7. O.Simma, E.Zebedin, N.Neugebauer, C.Schellack, A.Pilz, S.Chang-Rodriguez, K.Lingnau, E.Weisz, E.M.Putz, W.F.Pickl et al. Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance. Cancer Res 2009; 69:203-11; PMID:19118004; http://dx.doi.org/10.1158/0008-5472.CAN-08-1705
8. Q.Zhang, J.L.Sturgill, M.Kmieciak, K.Szczepanek, M.Derecka, C.Koebel, L.J.Graham, Y.Dai, S.Chen, S.Grant et al. The role of Tyk2 in regulation of breast cancer growth. J Interferon Cytokine Res 2011; 31:671-7; PMID:21864028; http://dx.doi.org/10.1089/jir.2011.0023
9. R.M.Vielnascher, E.Hainzl, N.R.Leitner, M.Rammerstorfer, D.Popp, A.Witalisz, R.Rom, M.Karaghiosoff, T.Kolbe, S.Muller et al. Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance. Transgenic Res 2014; 23:519-29; PMID:24696087; http://dx.doi.org/10.1007/s11248-014-9795-y
10. K.Shimoda, H.Tsutsui, K.Aoki, K.Kato, T.Matsuda, A.Numata, K.Takase, T.Yamamoto, H.Nukina, T.Hoshino et al. Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice. Blood 2002; 99:2094-9; PMID:11877284; http://dx.doi.org/10.1182/blood.V99.6.2094
11. D.Stoiber, B.Kovacic, C.Schuster, C.Schellack, M.Karaghiosoff, R.Kreibich, E.Weisz, M.Artwohl, O.C.Kleine, M.Muller et al. TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest 2004; 114:1650-8; PMID:15578097; http://dx.doi.org/10.1172/JCI200422315
12. U.Schleicher, J.Mattner, M.Blos, H.Schindler, M.Rollinghoff, M.Karaghiosoff, M.Muller, G.Werner-Felmayer, C.Bogdan. Control of Leishmania major in the absence of Tyk2 kinase. Eur J Immunol 2004; 34:519-29; PMID:14768057; http://dx.doi.org/10.1002/eji.200324465
13. Y.Minegishi, M.Saito, T.Morio, K.Watanabe, K.Agematsu, S.Tsuchiya, H.Takada, T.Hara, N.Kawamura, T.Ariga et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006; 25:745-55; PMID:17088085; http://dx.doi.org/10.1016/j.immuni.2006.09.009
14. S.S.Kilic, M.Hacimustafaoglu, S.Boisson-Dupuis, A.Y.Kreins, A.V.Grant, L.Abel, J.L.Casanova. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J Pediatr 2012; 160:1055-7; PMID:22402565; http://dx.doi.org/10.1016/j.jpeds.2012.01.056
15. M.Ishizaki, R.Muromoto, T.Akimoto, Y.Sekine, S.Kon, M.Diwan, H.Maeda, S.Togi, K.Shimoda, K.Oritani et al. Tyk2 is a therapeutic target for psoriasis-like skin inflammation. Int Immunol 2014; 26:257-67; PMID:24345760; http://dx.doi.org/10.1093/intimm/dxt062
16. J.Liang, V.Tsui, A.Van Abbema, L.Bao, K.Barrett, M.Beresini, L.Berezhkovskiy, W.S.Blair, C.Chang, J.Driscoll et al. Lead identification of novel and selective TYK2 inhibitors. Eur J Med Chem 2013; 67:175-87; PMID:23867602; http://dx.doi.org/10.1016/j.ejmech.2013.03.070
17. Y.Liang, Y.Zhu, Y.Xia, H.Peng, X.K.Yang, Y.Y.Liu, W.D.Xu, H.F.Pan, D.Q.Ye. Therapeutic potential of tyrosine kinase 2 in autoimmunity. Expert Opin Ther Targets 2014; 18:571-80; PMID:24654603; http://dx.doi.org/10.1517/14728222.2014.892925
18. C.J.Menet. Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases. Pharm Pat Anal 2014; 3:449-66; PMID:25291316; http://dx.doi.org/10.4155/ppa.14.23
19. P.Norman. Evaluation of WO2013125543, WO2013146963 and EP2634185: the first Tyk2 inhibitors from Takeda and Sareum. Expert Opin Ther Pat 2014; 24:361-8; PMID:24386992; http://dx.doi.org/10.1517/13543776.2014.864637
20. M.G.Works, B.Song, P.Kibler, M.J.Tanga, A.K.Galande, A.D'Andrea. Design of a peptide inhibitor of tyrosine kinase 2. Protein Pept Lett 2014; 21:419-25; PMID:24304386; http://dx.doi.org/10.2174/0929866520666131203101841
21. T.Sanda, J.W.Tyner, A.Gutierrez, V.N.Ngo, J.Glover, B.H.Chang, A.Yost, W.Ma, A.G.Fleischman, W.Zhou et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov 2013; 3:564-77; PMID:23471820; http://dx.doi.org/10.1158/2159-8290.CD-12-0504
22. T.Velusamy, M.J.Kiel, A.A.Sahasrabuddhe, D.Rolland, C.A.Dixon, N.G.Bailey, B.L.Betz, N.A.Brown, A.C.Hristov, R.A.Wilcox et al. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood 2014; 124(25):3768-71; PMID:25349176; http://dx.doi.org/10.1182/blood-2014-07-588434
23. H.Ide, T.Nakagawa, Y.Terado, Y.Kamiyama, S.Muto, S.Horie. Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells. Biochem Biophys Res Commun 2008; 369:292-6; PMID:17920038; http://dx.doi.org/10.1016/j.bbrc.2007.08.160
24. E.Caldas-Lopes, L.Cerchietti, J.H.Ahn, C.C.Clement, A.I.Robles, A.Rodina, K.Moulick, T.Taldone, A.Gozman, Y.Guo et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A 2009; 106:8368-73; PMID:19416831; http://dx.doi.org/10.1073/pnas.0903392106
25. J.Ragimbeau, E.Dondi, A.Alcover, P.Eid, G.Uze, S.Pellegrini. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J 2003; 22:537-47; PMID:12554654; http://dx.doi.org/10.1093/emboj/cdg038
26. M.C.Gauzzi, G.Barbieri, M.F.Richter, G.Uze, L.Ling, M.Fellous, S.Pellegrini. The amino-terminal region of Tyk2 sustains the level of interferon alpha receptor 1, a component of the interferon alpha/beta receptor. Proc Natl Acad Sci U S A 1997; 94:11839-44; PMID:9342324; http://dx.doi.org/10.1073/pnas.94.22.11839
27. Z.Li, M.Gakovic, J.Ragimbeau, M.L.Eloranta, L.Ronnblom, F.Michel, S.Pellegrini. Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent. J Immunol 2013; 190:2335-44; PMID:23359498; http://dx.doi.org/10.4049/jimmunol.1203118
28. R.Potla, T.Koeck, J.Wegrzyn, S.Cherukuri, K.Shimoda, D.P.Baker, J.Wolfman, S.M.Planchon, C.Esposito, B.Hoit et al. Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes. Mol Cell Biol 2006; 26:8562-71; PMID:16982690; http://dx.doi.org/10.1128/MCB.00497-06
29. M.R.Rani, D.W.Leaman, Y.Han, S.Leung, E.Croze, E.N.Fish, A.Wolfman, R.M.Ransohoff. Catalytically active TYK2 is essential for interferon-beta-mediated phosphorylation of STAT3 and interferon-alpha receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase. J Biol Chem 1999; 274:32507-11; PMID:10542297; http://dx.doi.org/10.1074/jbc.274.45.32507
30. C.M.Ahmed, E.N.Noon-Song, K.Kemppainen, M.P.Pascalli, H.M.Johnson. Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy. J Neuroimmunol 2013; 254:101-9; PMID:23110939; http://dx.doi.org/10.1016/j.jneuroim.2012.10.006
31. M.Prchal-Murphy, C.Semper, C.Lassnig, B.Wallner, C.Gausterer, I.Teppner-Klymiuk, J.Kobolak, S.Muller, T.Kolbe, M.Karaghiosoff et al. TYK2 kinase activity is required for functional type I interferon responses in vivo. PLoS One 2012; 7:e39141; PMID:22723949; http://dx.doi.org/10.1371/journal.pone.0039141
32. N.D.Huntington, C.A.Vosshenrich, J.P.Di Santo. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 2007; 7:703-14; PMID:17717540; http://dx.doi.org/10.1038/nri2154
33. D.K.Sojka, B.Plougastel-Douglas, L.Yang, M.A.Pak-Wittel, M.N.Artyomov, Y.Ivanova, C.Zhong, J.M.Chase, P.B.Rothman, J.Yu et al. Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells. Elife 2014; 3:e01659; PMID:24714492; http://dx.doi.org/10.7554/eLife.01659
34. H.Peng, X.Jiang, Y.Chen, D.K.Sojka, H.Wei, X.Gao, R.Sun, W.M.Yokoyama, Z.Tian. Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. J Clin Invest 2013; 123:1444-56; PMID:23524967; http://dx.doi.org/10.1172/JCI66381
35. L.L.Lanier. NK cell recognition. Annu Rev Immunol 2005; 23:225-74; PMID:15771571; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115526
36. R.P.Sullivan, J.W.Leong, T.A.Fehniger. MicroRNA regulation of natural killer cells. Front Immunol 2013; 4:44; PMID:23450173; http://dx.doi.org/10.3389/fimmu.2013.00044
37. T.A.Fehniger, S.F.Cai, X.Cao, A.J.Bredemeyer, R.M.Presti, A.R.French, T.J.Ley. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity 2007; 26:798-811; PMID:17540585; http://dx.doi.org/10.1016/j.immuni.2007.04.010
38. E.Vivier, D.H.Raulet, A.Moretta, M.A.Caligiuri, L.Zitvogel, L.L.Lanier, W.M.Yokoyama, S.Ugolini. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331:44-9; PMID:21212348; http://dx.doi.org/10.1126/science.1198687
39. J.R.Ortaldo, E.W.Bere, D.Hodge, H.A.Young. Activating Ly-49 NK receptors: central role in cytokine and chemokine production. J Immunol 2001; 166:4994-9; PMID:11290779; http://dx.doi.org/10.4049/jimmunol.166.8.4994
40. T.Mizutani, N.Neugebauer, E.M.Putz, N.Moritz, O.Simma, E.Zebedin-Brandl, D.Gotthardt, W.Warsch, E.Eckelhart, H.P.Kantner et al. Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology 2012; 1:1027-37; PMID:23170251; http://dx.doi.org/10.4161/onci.21284
41. C.K.Lee, D.T.Rao, R.Gertner, R.Gimeno, A.B.Frey, D.E.Levy. Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol 2000; 165:3571-7; PMID:11034357; http://dx.doi.org/10.4049/jimmunol.165.7.3571
42. J.Guan, S.M.Miah, Z.S.Wilson, T.K.Erick, C.Banh, L.Brossay. Role of type I interferon receptor signaling on NK cell development and functions. PLoS One 2014; 9:e111302; PMID:25333658; http://dx.doi.org/10.1371/journal.pone.0111302
43. S.H.Robbins, M.S.Tessmer, L.Van Kaer, L.Brossay. Direct effects of T-bet and MHC class I expression, but not STAT1, on peripheral NK cell maturation. Eur J Immunol 2005; 35:757-65; PMID:15719366; http://dx.doi.org/10.1002/eji.200425797
44. E.M.Putz, D.Gotthardt, G.Hoermann, A.Csiszar, S.Wirth, A.Berger, E.Straka, D.Rigler, B.Wallner, A.M.Jamieson et al. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep 2013; 4:437-44; PMID:23933255; http://dx.doi.org/10.1016/j.celrep.2013.07.012
45. X.Wu, Y.Chen, R.Sun, H.Wei, Z.Tian. Impairment of hepatic NK cell development in IFN-gamma deficient mice. Cytokine 2012; 60:616-25; PMID:22921904; http://dx.doi.org/10.1016/j.cyto.2012.07.012
46. C.Haan, C.Rolvering, F.Raulf, M.Kapp, P.Druckes, G.Thoma, I.Behrmann, H.G.Zerwes. Jak1 has a dominant role over Jak3 in signal transduction through gammac-containing cytokine receptors. Chem Biol 2011; 18:314-23; PMID:21439476; http://dx.doi.org/10.1016/j.chembiol.2011.01.012
47. R.Trotta, L.Chen, S.Costinean, S.Josyula, B.L.Mundy-Bosse, D.Ciarlariello, C.Mao, E.L.Briercheck, K.K.McConnell, A.Mishra et al. Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells. Blood 2013; 121:3126-34; PMID:23422749; http://dx.doi.org/10.1182/blood-2012-12-467597
48. Y.Hayakawa, M.J.Smyth. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol 2006; 176:1517-24; PMID:16424180; http://dx.doi.org/10.4049/jimmunol.176.3.1517
49. M.Luetke-Eversloh, B.B.Cicek, F.Siracusa, J.T.Thom, A.Hamann, S.Frischbutter, R.Baumgrass, H.D.Chang, A.Thiel, J.Dong et al. NK cells gain higher IFN-gamma competence during terminal differentiation. Eur J Immunol 2014; 44:2074-84; PMID:24752800; http://dx.doi.org/10.1002/eji.201344072
50. S.Zhu, P.V.Phatarpekar, C.J.Denman, V.V.Senyukov, S.S.Somanchi, H.T.Nguyen-Jackson, E.M.Mace, A.F.Freeman, S.S.Watowich, J.S.Orange et al. Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation. Blood 2014; 124:403-11; PMID:24891320; http://dx.doi.org/10.1182/blood-2013-05-499707
51. D.Gotthardt, E.M.Putz, E.Straka, P.Kudweis, M.Biaggio, V.Poli, B.Strobl, M.Muller, V.Sexl. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood 2014; 124:2370-9; PMID:25185262; http://dx.doi.org/10.1182/blood-2014-03-564450
52. R.P.Sullivan, L.A.Fogel, J.W.Leong, S.E.Schneider, R.Wong, R.Romee, T.H.Thai, V.Sexl, S.J.Matkovich, G.W.Dorn, 2nd et al. MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways. J Immunol 2013; 191:5904-13; PMID:24227772; http://dx.doi.org/10.4049/jimmunol.1301950
53. R.Trotta, L.Chen, D.Ciarlariello, S.Josyula, C.Mao, S.Costinean, L.Yu, J.P.Butchar, S.Tridandapani, C.M.Croce et al. miR-155 regulates IFN-gamma production in natural killer cells. Blood 2012; 119:3478-85; PMID:22378844; http://dx.doi.org/10.1182/blood-2011-12-398099
54. T.A.Fehniger, T.Wylie, E.Germino, J.W.Leong, V.J.Magrini, S.Koul, C.R.Keppel, S.E.Schneider, D.C.Koboldt, R.P.Sullivan et al. Next-generation sequencing identifies the natural killer cell microRNA transcriptome. Genome Res 2010; 20:1590-604; PMID:20935160; http://dx.doi.org/10.1101/gr.107995.110
55. C.J.Chan, D.M.Andrews, N.M.McLaughlin, H.Yagita, S.Gilfillan, M.Colonna, M.J.Smyth. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol 2010; 184:902-11; PMID:20008292; http://dx.doi.org/10.4049/jimmunol.0903225
56. S.Gilfillan, C.J.Chan, M.Cella, N.M.Haynes, A.S.Rapaport, K.S.Boles, D.M.Andrews, M.J.Smyth, M.Colonna. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 2008; 205:2965-73; PMID:19029380; http://dx.doi.org/10.1084/jem.20081752
57. J.L.Wong, E.Berk, R.P.Edwards, P.Kalinski. IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res 2013; 73:4653-62; PMID:23761327; http://dx.doi.org/10.1158/0008-5472.CAN-12-4366
58. M.Zijlstra, M.Bix, N.E.Simister, J.M.Loring, D.H.Raulet, R.Jaenisch. Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells. Nature 1990; 344:742-6; PMID:2139497; http://dx.doi.org/10.1038/344742a0
59. R.Kiessling, E.Klein, H.Wigzell. “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975; 5:112-7; PMID:1234049; http://dx.doi.org/10.1002/eji.1830050208
60. Kärre, K, Ljunggren, H G, Piontek, G, Kiessling, R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319:675–678. PMID 3951539; http//dx.doi.org/10.1038/319675a0
61. A.Cerwenka, J.L.Baron, L.L.Lanier. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A 2001; 98:11521-6; PMID:11562472; http://dx.doi.org/10.1073/pnas.201238598
62. M.Karaghiosoff, R.Steinborn, P.Kovarik, G.Kriegshauser, M.Baccarini, B.Donabauer, U.Reichart, T.Kolbe, C.Bogdan, T.Leanderson et al. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat Immunol 2003; 4:471-7; PMID:12679810; http://dx.doi.org/10.1038/ni910